导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.14% | 1937/4773 |
| 近一周 | -2.37% | 1970/5462 |
| 近一月 | -3.87% | 2035/5421 |
| 近一季 | -4.42% | 1629/5209 |
| 近半年 | -0.35% | 1276/4920 |
| 近一年 | 4.13% | 1789/4366 |
| 近两年 | 45.59% | 1619/2954 |
| 近三年 | 30.84% | 1022/2253 |
| 成立以来 | 89.51% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.09% 3029/4961 |
10.41% 2416/5312 |
- - |
- - |
| 2025 | 16.61% 2437/4813 |
-0.98% 2506/3635 |
1.56% 2279/4076 |
14.17% 2940/4524 |
1.57% 1324/4813 |
| 2024 | 18.96% 567/3463 |
3.65% 527/2808 |
-0.22% 710/3014 |
16.14% 1526/3129 |
-0.96% 1553/3463 |
| 2023 | -7.62% 932/2656 |
4.54% 925/2280 |
-3.54% 820/2385 |
-2.21% 639/2515 |
-6.32% 1721/2655 |
| 2022 | -17.97% 646/2207 |
-13.80% 838/1919 |
7.16% 518/2016 |
-12.74% 775/2113 |
1.76% 1155/2208 |
| 2021 | 4.36% 584/1822 |
-1.48% 499/1255 |
5.81% 790/1330 |
-2.26% 559/1466 |
2.42% 597/1822 |
| 2020 | 38.89% 344/1250 |
-7.73% 567/1028 |
13.36% 626/1067 |
14.97% 246/1164 |
15.49% 203/1184 |
| 2019 | 40.86% 245/1092 |
27.29% 350/754 |
1.38% 132/804 |
1.68% 375/850 |
7.36% 444/918 |
| 2018 | -25.45% 352/834 |
- - |
- - |
- - |
-16.39% 636/691 |
| 2017 | 7.56% 318/714 |
- - |
- - |
- - |
- - |
| 2016 | -14.50% 338/605 |
- - |
- - |
- - |
- - |
| 2015 | 23.44% 98/575 |
- - |
- - |
- - |
- - |
| 2014 | 29.47% 167/237 |
- - |
- - |
- - |
- - |
| 2013 | 17.98% 17/186 |
- - |
- - |
- - |
- - |
| 2012 | -3.17% 136/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 诺安沪深300指数增强A VS. 长安沪深300非周期A(740101) |